Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Data At ASCO From J&J Zytiga Trial’s Early End = Intel For Medivation’s MDV3100 Program

Jun 18 2012

• By Shirley Haley

Related Content

Zytiga Pre-chemo Data Impress At ASCO, But Early Trial Termination Could Be An Issue

Jun 03 2012

More Competition In Prostate Cancer? Medivation’s Enzalutamide Now With FDA

May 22 2012

<i>Sutent</i> Pancreatic Tumor Study Shows Regulatory Pitfalls Of Stopping Early

Apr 18 2011

Sutent Cleared For Pancreatic Tumors, But With Caveat On Efficacy

May 23 2011

<i>Zytiga</i> Cleared Fast In Refractory CRPC, Can It Also Move To Earlier Use?

May 02 2011

Dendreon Defends <i>Provenge</i>’s Stake Against Arrival Of Abiraterone

May 09 2011

Related Companies

Medivation, Inc.

Astellas Pharma, Inc.

Dendreon Corporation

Sanofi

Johnson & Johnson

Johnson & Johnson

Additional Topics

Clinical Trials BioPharmaceutical

More from Clinical Trials

More from R&D

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window